Personalis 01-PS-001
Trial Overview
Official Title
Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I)
Study Purpose
Evaluate the correlation of Minimal Residual Disease detection by NeXT Personal CTA (a molecular test) to pathological Complete Response (pCR) after neoadjuvant chemotherapy (NAC) in stage I-III triple negative breast cancer (TNBC)
Diagnosis
Early stage 1-111 triple negative breast cancerEligibility
Documented early stage triple negative breast cancer not having started treatment
Intervention
Blood draw only
For more information visit, Clinicaltrials.gov
Key Participation Requirements
Trial Location(s)
Gender
male or female
Age
19 and older
Enrollment Status
Recruiting
Phase
Phase I
Methodist Health System Trial Code
01-PS-001